Dec 30 (Reuters) - CARsgen Therapeutics Holdings Ltd 2171.HK:
CARSGEN ANNOUNCES POSITIVE TOPLINE RESULTS FROM CHINA GC/GEJ PIVOTAL PHASE II CLINICAL TRIAL OF CLAUDIN18.2 CAR-T (SATRI-CEL)
CARSGEN THERAPEUTICS HOLDINGS LTD - STUDY MEETS PRIMARY ENDPOINT OF IMPROVED PFS
CARSGEN THERAPEUTICS HOLDINGS LTD: ANTICIPATE SUBMITTING AN NDA TO NMPA IN FIRST HALF OF 2025
Source text: ID:nPn8yM75Ja
Further company coverage: 2171.HK
((Reuters.Briefs@thomsonreuters.com;))